EA202190358A1 - Способы генной терапии для контроля функции органов - Google Patents
Способы генной терапии для контроля функции органовInfo
- Publication number
- EA202190358A1 EA202190358A1 EA202190358A EA202190358A EA202190358A1 EA 202190358 A1 EA202190358 A1 EA 202190358A1 EA 202190358 A EA202190358 A EA 202190358A EA 202190358 A EA202190358 A EA 202190358A EA 202190358 A1 EA202190358 A1 EA 202190358A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- organ
- function
- control
- organ function
- gene therapy
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 title 1
- 239000013603 viral vector Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001276 controlling effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712669P | 2018-07-31 | 2018-07-31 | |
| PCT/US2019/044290 WO2020028466A1 (en) | 2018-07-31 | 2019-07-31 | Gene therapy methods to control organ function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190358A1 true EA202190358A1 (ru) | 2021-05-04 |
Family
ID=69230802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190358A EA202190358A1 (ru) | 2018-07-31 | 2019-07-31 | Способы генной терапии для контроля функции органов |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210301306A1 (https=) |
| EP (1) | EP3829718A4 (https=) |
| JP (2) | JP2021533126A (https=) |
| KR (1) | KR20210052450A (https=) |
| CN (1) | CN113301956B (https=) |
| AU (1) | AU2019315445A1 (https=) |
| BR (1) | BR112021001878A2 (https=) |
| CA (1) | CA3108324A1 (https=) |
| EA (1) | EA202190358A1 (https=) |
| IL (1) | IL280531A (https=) |
| MX (1) | MX2021001336A (https=) |
| PH (1) | PH12021550243A1 (https=) |
| SG (1) | SG11202101042SA (https=) |
| WO (1) | WO2020028466A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013134543A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Immune system neuromodulation and associated systems and methods |
| JP2017536187A (ja) | 2014-12-03 | 2017-12-07 | メタベンション インコーポレイテッド | 神経または他の組織を調節するためのシステムおよび方法 |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| CN115707773A (zh) * | 2021-08-20 | 2023-02-21 | 中国科学院深圳先进技术研究院 | 一种利用交感神经控制血管内皮细胞异质性的方法 |
| WO2023019565A1 (zh) * | 2021-08-20 | 2023-02-23 | 中国科学院深圳先进技术研究院 | 一种利用交感神经控制血管内皮细胞异质性的方法 |
| CN116019909B (zh) * | 2022-09-16 | 2025-07-29 | 上海市第十人民医院 | 一种CRISPR/Cas9纳米系统 |
| CN116115758B (zh) * | 2022-11-22 | 2024-12-03 | 上海市内分泌代谢病研究所 | Gabaa受体作为靶点在制备或筛选降血脂、治疗肥胖和/或改善代谢的药物中的应用 |
| CN120699131B (zh) * | 2024-12-04 | 2025-12-09 | 良渚实验室 | 治疗帕金森病的化学遗传学基因治疗新方案 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US6342390B1 (en) | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CA2566257A1 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof |
| WO2006110689A2 (en) * | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| RS61055B1 (sr) * | 2012-06-19 | 2020-12-31 | Univ Florida | Kompozicije i postupci za lečenje bolesti |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10711270B2 (en) * | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
| US20170218842A1 (en) * | 2016-02-02 | 2017-08-03 | General Electric Company | Adjusting Airflow Distortion in Gas Turbine Engine |
| WO2017136536A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| JP6968331B2 (ja) * | 2016-03-09 | 2021-11-17 | アサフ，ファディ | ニューロン性疾患の治療におけるニューロン調節のためのｄｒｅａｄｄの使用 |
| MA44546B1 (fr) * | 2016-06-15 | 2021-03-31 | Univ California | Virus adéno-associés variants et procédés d'utilisation |
| WO2018008770A1 (ja) * | 2016-07-06 | 2018-01-11 | 国立研究開発法人国立循環器病研究センター | 末梢神経を操作する方法、脳および脊髄を除く臓器などにおいて神経細胞機能を変化させる機能を発生させる方法、および新規疾病の予防または治療方法、ならびに末梢神経投与用医薬 |
| IL292382A (en) * | 2019-10-22 | 2022-06-01 | Applied Genetic Tech Corporation | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders |
-
2019
- 2019-07-31 JP JP2021505674A patent/JP2021533126A/ja active Pending
- 2019-07-31 US US17/264,752 patent/US20210301306A1/en active Pending
- 2019-07-31 BR BR112021001878-6A patent/BR112021001878A2/pt unknown
- 2019-07-31 WO PCT/US2019/044290 patent/WO2020028466A1/en not_active Ceased
- 2019-07-31 AU AU2019315445A patent/AU2019315445A1/en not_active Abandoned
- 2019-07-31 MX MX2021001336A patent/MX2021001336A/es unknown
- 2019-07-31 SG SG11202101042SA patent/SG11202101042SA/en unknown
- 2019-07-31 CA CA3108324A patent/CA3108324A1/en active Pending
- 2019-07-31 KR KR1020217005554A patent/KR20210052450A/ko not_active Ceased
- 2019-07-31 EA EA202190358A patent/EA202190358A1/ru unknown
- 2019-07-31 CN CN201980065036.9A patent/CN113301956B/zh active Active
- 2019-07-31 EP EP19845335.9A patent/EP3829718A4/en active Pending
-
2021
- 2021-01-31 IL IL280531A patent/IL280531A/en unknown
- 2021-02-01 PH PH12021550243A patent/PH12021550243A1/en unknown
-
2024
- 2024-01-10 JP JP2024001612A patent/JP2024041871A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3829718A1 (en) | 2021-06-09 |
| CN113301956B (zh) | 2025-06-24 |
| CA3108324A1 (en) | 2020-02-06 |
| PH12021550243A1 (en) | 2021-11-22 |
| KR20210052450A (ko) | 2021-05-10 |
| WO2020028466A1 (en) | 2020-02-06 |
| CN113301956A (zh) | 2021-08-24 |
| US20210301306A1 (en) | 2021-09-30 |
| JP2021533126A (ja) | 2021-12-02 |
| BR112021001878A2 (pt) | 2021-04-27 |
| EP3829718A4 (en) | 2022-06-22 |
| SG11202101042SA (en) | 2021-02-25 |
| AU2019315445A1 (en) | 2021-03-18 |
| MX2021001336A (es) | 2021-09-10 |
| JP2024041871A (ja) | 2024-03-27 |
| IL280531A (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190358A1 (ru) | Способы генной терапии для контроля функции органов | |
| Lingel et al. | CTLA-4 (CD152): A versatile receptor for immune-based therapy | |
| PH12019502870A1 (en) | Small molecule modulators of human sting | |
| JOP20210154A1 (ar) | مثبطات kif18a | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| EA201990747A1 (ru) | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
| MX2024011808A (es) | Metodos y sistemas para regular condicionalmente la expresion genica | |
| MX2023008760A (es) | Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a. | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| MY209860A (en) | Gene therapy vectors for treating heart disease | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| EA201890199A1 (ru) | Комбинированная терапия для лечения гемобластозов и солидных опухолей | |
| EA202092718A1 (ru) | Композиции для контроля патогенов и пути их применения | |
| MX2022002198A (es) | Composiciones y métodos para modular el empalme y la expresión de proteínas. | |
| JP2016512781A5 (https=) | ||
| JOP20210033B1 (ar) | جرعة ليلية مزمنة من لاسميديتان للوقاية من الصداع النصفي | |
| JOP20200252B1 (ar) | مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها | |
| WO2021216738A3 (en) | Compositions and methods of generating an immune response | |
| WO2019066490A3 (ko) | 유전자 발현 조절을 위한 인위적인 게놈 조작 | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| EA202092282A1 (ru) | Способы лечения минимального остаточного рака | |
| EA202192757A1 (ru) | Способ лечения опухолей | |
| MX2018009792A (es) | Imidazolilcarboxamidas sustituidas como plaguicidas. | |
| MX2023013697A (es) | Vectores vegetales, composiciones y usos relacionados con los mismos. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder |